

(12) PATENT APPLICATION PUBLICATION

(21) Application No.202441035619 A

(19) INDIA

(22) Date of filing of Application :06/05/2024

(43) Publication Date : 12/07/2024

(54) Title of the invention : COMPOSITION FOR TREATMENT OF NEURODEGENERATIVE DISEASES

(51) International classification :A61K0009000000, A61P0025280000, A61P0031100000, A61K0031050000, A61P0025000000

(86) International Application No :NA
Filing Date :NA

(87) International Publication No : NA

(61) Patent of Addition to Application Number :NA
Filing Date :NA

(62) Divisional to Application Number :NA
Filing Date :NA

(71)Name of Applicant :
1)JSS Academy of Higher Education & Research (Deemed to be university)
Address of Applicant :Sri Shivarathreshwara Nagara, Mysuru, Karnataka, India, Mysore -----

Name of Applicant : NA
Address of Applicant : NA

(72)Name of Inventor :
1)Bhargav Shreevatsa
Address of Applicant :Department of Biotechnology and Bioinformatics, JSS Academy of Higher Education and Research, Mysuru, Karnataka – 570015, India Mysore -----

2)Chandan Dharmashekara
Address of Applicant :Department of Biotechnology and Bioinformatics, JSS Academy of Higher Education and Research, Mysuru, Karnataka – 570015, India Mysore -----

3)Anisha S Jain
Address of Applicant :Department of Microbiology, JSS Academy of Higher Education and Research, Mysuru, Karnataka – 570015, India Mysore -----

4)Shiva Prasad Kollur
Address of Applicant :School of Physical Sciences, Amrita Vishwa Vidyapeetham, Mysuru Campus, Mysuru, Karnataka – 570026, India Mysore -----

5)Chandan Shivamallu
Address of Applicant :Department of Biotechnology and Bioinformatics, JSS Academy of Higher Education and Research, Mysuru, Karnataka – 570015 Mysore -----

(57) Abstract :

A COMPOSITION FOR TREATMENT OF NEURODEGENERATIVE DISEASES ABSTRACT 5 A composition for treatment of neurodegenerative diseases is provided. The composition includes a combination of Rifampicin (Rifampin) as an antibiotic, Lamisil (Terbinafine) as an antifungal agent, curcumin as an anti-inflammatory agent, and cannabidiol (CBD) as a lipophilic potentiating agent, in synergistically effective proportions. The composition provides reduced likelihood of the body developing immunity to the treatment over time. The composition includes about 25 milligram (mg) to 500 mg of Rifampicin (Rifampin) is from administered. The composition includes about 25 mg to 400 mg of Lamisil (terbinafine). The composition includes about 5 mg to 40 mg of lipophilic statin. The composition is administered every 12 hours, depending on age and weight of a patient. The neurodegenerative disease includes multiple sclerosis. The 15 composition is presented in a single oral form including at least one of: a pill, a capsule, or a tablet.

No. of Pages : 32 No. of Claims : 10